Day: May 27, 2025

SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”), a leading fintech platform serving the Bitcoin mining ecosystem, today announced strategic initiatives to strengthen its treasury plan and expand its product offering.  Strategic Allocation into Tether Gold (XAUt)Antalpha intends to allocate up to US $40 million equivalent in XAUt at market price from now until June 30, 2026. The Company views this allocation as a strategic hedge against macroeconomic volatility, a tool to diversify its institutional collateral base, and a means to offer its clients access to stable-value lending solutions to hedge against periods of market uncertainty. The Company believes that XAUt offers strong strategic value for institutional asset allocation, particularly in its potential...

BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed using Biolojic’s Multibody Platform, which generates Antibodies capable of addressing multiple disease targetsCollaboration builds on Teva’s Pivot to Growth strategy to step up innovation in Teva’s innovative pipelineREHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology company using computational biology and artificial intelligence to design next generation, multifunctional antibodies known as multibodies, announced today that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin) and IL-13....

CHICAGO, May 27, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that Jon Levin, President of GCM Grosvenor, will present at the Morgan Stanley 2025 U.S. Financials, Payments & Commercial Real Estate Conference on Tuesday, June 10, 2025, at 3:15 PM EDT. A link to the live audio webcast of the presentation will be available on GCM Grosvenor’s public shareholders website and the event website. For those unable to listen to the live audio webcast, a replay will be available for 90 days following the presentation. About GCM Grosvenor GCM Grosvenor (Nasdaq: GCMG) is a global alternative asset management solutions provider with approximately $82 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute...

WILMINGTON, Del., May 27, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that the company will be presenting at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, 2025, at 4:20 PM ET. The event will be webcast live and an archived replay of the presentation will also be available following the conference. For more information, please visit the Investors section of the company’s website closer to the event. About InterDigital® InterDigital is a global research and development company focused primarily on wireless, video, artificial intelligence (“AI”), and related technologies. We design and develop foundational technologies that enable connected, immersive experiences in a broad range of communications and entertainment...

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia continue without modification. The DSMB recommendation followed a review of unblinded safety data from the first 115 patients dosed as of the May 2, 2025 cutoff date. The trial is fully enrolled and collection of data over the 12-week period is continuing. “We are pleased with the favorable DSMB meeting outcome...